We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

101 hedge funds and large institutions have $248M invested in UroGen Pharma in 2023 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 8

105% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $509K

82% more capital invested

Capital invested by funds: $137M → $248M (+$112M)

59% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 22

19% more funds holding

Funds holding: 85 → 101 (+16)

2.2% more ownership

Funds ownership: 56.33% → 58.53% (+2.2%)

Holders
101
Holders Change
+16
Holders Change %
+18.82%
% of All Funds
1.6%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
35
Reduced
22
Closed
8
Calls
$1.04M
Puts
$509K
Net Calls
+$533K
Net Calls Change
+$640K

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$42.1M
2
RCM
RA Capital Management
Massachusetts
+$23.8M
3
SCM
Silverarc Capital Management
Massachusetts
+$8.17M
4
SCM
Soleus Capital Management
Connecticut
+$5.97M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.33M

Top Sellers

Rank Fund Capital Flow
1
CI
Clal Insurance
Israel
-$4.93M
2
SCM
Stonepine Capital Management
Oregon
-$4.64M
3
OM
Opaleye Management
Massachusetts
-$4.01M
4
MMH
Menora Mivtachim Holdings
Israel
-$3.64M
5
Wells Fargo
Wells Fargo
California
-$3.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
KHLMTHM
51
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet
Israel
$314K – – –
Susquehanna International Group
52
Susquehanna International Group
Pennsylvania
$283K +$119K +7,441 +58%
UBS Group
53
UBS Group
Switzerland
$269K +$82K +5,111 +36%
JP Morgan Chase
54
JP Morgan Chase
New York
$267K -$516K -32,174 -63%
Two Sigma Advisers
55
Two Sigma Advisers
New York
$265K +$303K +18,900 New
Royal Bank of Canada
56
Royal Bank of Canada
Ontario, Canada
$239K +$12.3K +764 +5%
Verition Fund Management
57
Verition Fund Management
Connecticut
$238K +$273K +17,017 New
CAM
58
Cresset Asset Management
Illinois
$234K -$7.66K -477 -3%
VCM
59
Vivaldi Capital Management
Illinois
$231K +$79.6K +4,961 +43%
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$229K +$181K +11,277 +221%
AI
61
Atom Investors
Texas
$219K +$251K +15,660 New
PCIG
62
Partners Capital Investment Group
Massachusetts
$216K – – –
DA
63
Denali Advisors
California
$200K -$75.4K -4,700 -25%
Federated Hermes
64
Federated Hermes
Pennsylvania
$184K +$211K +13,130 New
Mirae Asset Global Investments
65
Mirae Asset Global Investments
South Korea
$158K +$2.9K +181 +2%
Deutsche Bank
66
Deutsche Bank
Germany
$147K +$147K +9,143 +667%
EFG
67
Ethos Financial Group
Pennsylvania
$147K – – –
MIM
68
MetLife Investment Management
New Jersey
$146K – – –
TRCT
69
Tower Research Capital (TRC)
New York
$146K +$155K +9,686 +1,376%
GCP
70
GSA Capital Partners
United Kingdom
$143K +$164K +10,189 New
Jane Street
71
Jane Street
New York
$141K -$52.9K -3,298 -25%
Invesco
72
Invesco
Georgia
$141K +$161K +10,055 New
AIG
73
American International Group
New York
$137K +$5.59K +348 +4%
New York State Common Retirement Fund
74
New York State Common Retirement Fund
New York
$120K +$3.21K +200 +2%
Citadel Advisors
75
Citadel Advisors
Florida
$98K -$658K -40,984 -85%
1 2
3
4 5

URGN Hedge Fund Activity: Q3 2023 in Review

101 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q3 2023, worth a combined $248M — up 82% from $137M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new URGN positions and 8 closed out — a net gain of 16 holders — while 35 added to existing stakes and 22 trimmed.

The largest buyer was Great Point Partners, opening a new position worth an estimated $42.1M. The largest seller was Clal Insurance, cutting an estimated $4.93M.

  • 101 institutional investors held UroGen Pharma (URGN) as of Q3 2023, up from 85 in Q2 2023.
  • Funds reported $248M of UroGen Pharma stock for Q3 2023, up 82% quarter-over-quarter.
  • 24 funds opened new UroGen Pharma positions in Q3 2023 and 8 closed out, a net change of +16 holders.
  • The largest UroGen Pharma buyer in Q3 2023 was Great Point Partners, an estimated $42.1M added.
  • The largest UroGen Pharma seller in Q3 2023 was Clal Insurance, an estimated $4.93M sold.

Based on aggregated 13F filings for Q3 2023.